KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Working Capital Changes (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Other Working Capital Changes for 18 consecutive years, with $198.6 million as the latest value for Q1 2026.

  • For Q1 2026, Other Working Capital Changes rose 1022.03% year-over-year to $198.6 million; the TTM value through Mar 2026 reached $556.2 million, up 231.86%, while the annual FY2025 figure was $375.3 million, 64.75% up from the prior year.
  • Other Working Capital Changes hit $198.6 million in Q1 2026 for Regeneron Pharmaceuticals, down from $423.9 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $526.3 million in Q2 2024 and bottomed at -$252.0 million in Q3 2024.
  • Average Other Working Capital Changes over 5 years is $58.1 million, with a median of $17.7 million recorded in 2025.
  • Year-over-year, Other Working Capital Changes plummeted 1793.75% in 2022 and then surged 1074.78% in 2024.
  • Regeneron Pharmaceuticals' Other Working Capital Changes stood at -$18.7 million in 2022, then plummeted by 1218.18% to -$246.5 million in 2023, then skyrocketed by 49.53% to -$124.4 million in 2024, then skyrocketed by 440.76% to $423.9 million in 2025, then crashed by 53.15% to $198.6 million in 2026.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at $198.6 million, $423.9 million, and $76.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.